JPWO2022098936A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022098936A5 JPWO2022098936A5 JP2023527473A JP2023527473A JPWO2022098936A5 JP WO2022098936 A5 JPWO2022098936 A5 JP WO2022098936A5 JP 2023527473 A JP2023527473 A JP 2023527473A JP 2023527473 A JP2023527473 A JP 2023527473A JP WO2022098936 A5 JPWO2022098936 A5 JP WO2022098936A5
- Authority
- JP
- Japan
- Prior art keywords
- tumor
- specific
- subject
- specific neoantigens
- immunogenic composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010028980 Neoplasm Diseases 0.000 claims 54
- 238000000034 method Methods 0.000 claims 19
- 239000000203 mixture Substances 0.000 claims 17
- 230000002163 immunogen Effects 0.000 claims 15
- 108090000765 processed proteins & peptides Proteins 0.000 claims 12
- 229920001184 polypeptide Polymers 0.000 claims 11
- 102000004196 processed proteins & peptides Human genes 0.000 claims 11
- 230000028993 immune response Effects 0.000 claims 7
- 230000006472 autoimmune response Effects 0.000 claims 4
- 201000001441 melanoma Diseases 0.000 claims 3
- 239000002773 nucleotide Substances 0.000 claims 3
- 125000003729 nucleotide group Chemical group 0.000 claims 3
- 210000001519 tissue Anatomy 0.000 claims 3
- 206010005003 Bladder cancer Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 230000004044 response Effects 0.000 claims 2
- 238000012163 sequencing technique Methods 0.000 claims 2
- 210000004881 tumor cell Anatomy 0.000 claims 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 1
- 208000003950 B-cell lymphoma Diseases 0.000 claims 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 108020004414 DNA Proteins 0.000 claims 1
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 claims 1
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000000389 T-cell leukemia Diseases 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 1
- 206010057644 Testis cancer Diseases 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 210000000612 antigen-presenting cell Anatomy 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 210000004443 dendritic cell Anatomy 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 238000010801 machine learning Methods 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 239000013612 plasmid Substances 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 201000003120 testicular cancer Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063110711P | 2020-11-06 | 2020-11-06 | |
| US63/110,711 | 2020-11-06 | ||
| PCT/US2021/058162 WO2022098936A1 (en) | 2020-11-06 | 2021-11-05 | Selecting neoantigens for personalized cancer vaccine |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023549342A JP2023549342A (ja) | 2023-11-24 |
| JP2023549342A5 JP2023549342A5 (https=) | 2024-11-12 |
| JPWO2022098936A5 true JPWO2022098936A5 (https=) | 2024-11-12 |
Family
ID=78695860
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023527473A Pending JP2023549342A (ja) | 2020-11-06 | 2021-11-05 | 個別化されたがんワクチンのためのネオアンチゲンの選択 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20230197192A1 (https=) |
| EP (1) | EP4241274A1 (https=) |
| JP (1) | JP2023549342A (https=) |
| CN (1) | CN116802738A (https=) |
| WO (1) | WO2022098936A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2024508677A (ja) * | 2021-02-05 | 2024-02-28 | アマゾン テクノロジーズ インコーポレイテッド | 個別化がんワクチン用ネオアンチゲンのランク付け |
| WO2025128926A1 (en) | 2023-12-13 | 2025-06-19 | Amazon Technologies, Inc. | Methods of identifying and treating individuals with elevated cancer risk |
| US20250197924A1 (en) | 2023-12-15 | 2025-06-19 | Amazon Technologies, Inc. | Methods for selection and combination of sequencing results from biological samples for neoantigen scoring |
| WO2026073127A1 (en) | 2024-09-30 | 2026-04-02 | Amazon Technologies, Inc. | Dual assay to boost accuracy of detected actionable variants in liquid biopsy |
| WO2026072916A1 (en) | 2024-09-30 | 2026-04-02 | Amazon Technologies, Inc. | Structural variant detection in circulating tumor dna |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4722848A (en) | 1982-12-08 | 1988-02-02 | Health Research, Incorporated | Method for immunizing animals with synthetically modified vaccinia virus |
| US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
| US5019369A (en) | 1984-10-22 | 1991-05-28 | Vestar, Inc. | Method of targeting tumors in humans |
| US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
| US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| US5204253A (en) | 1990-05-29 | 1993-04-20 | E. I. Du Pont De Nemours And Company | Method and apparatus for introducing biological substances into living cells |
| CA2646539A1 (en) | 2006-03-23 | 2007-09-27 | Novartis Ag | Imidazoquinoxaline compounds as immunomodulators |
| CA2646891A1 (en) | 2006-03-23 | 2007-09-27 | Novartis Ag | Immunopotentiating compounds |
| KR20150093658A (ko) * | 2012-10-09 | 2015-08-18 | 파이브3 제노믹스, 엘엘씨 | 종양 클론형성능 분석을 위한 시스템 및 방법 |
| RU2729116C2 (ru) * | 2015-12-16 | 2020-08-04 | Гритстоун Онколоджи, Инк. | Идентификация, производство и применение неоантигенов |
| US10364468B2 (en) * | 2016-01-13 | 2019-07-30 | Seven Bridges Genomics Inc. | Systems and methods for analyzing circulating tumor DNA |
| EP3652318A1 (en) * | 2017-07-11 | 2020-05-20 | Actym Therapeutics, Inc. | Engineered immunostimulatory bacterial strains and uses thereof |
| JP7763588B2 (ja) * | 2017-09-05 | 2025-11-04 | グリットストーン バイオ インコーポレイテッド | Ｔ細胞療法用の新生抗原の特定法 |
| CN112771214B (zh) * | 2018-09-27 | 2025-06-13 | 耐考德治疗股份有限公司 | 用于选择新表位的方法 |
| AU2019404547B2 (en) * | 2018-12-21 | 2025-01-30 | Biontech Us Inc. | Method and systems for prediction of HLA class II-specific epitopes and characterization of CD4+ T cells |
-
2021
- 2021-11-05 US US17/616,145 patent/US20230197192A1/en active Pending
- 2021-11-05 JP JP2023527473A patent/JP2023549342A/ja active Pending
- 2021-11-05 EP EP21810856.1A patent/EP4241274A1/en active Pending
- 2021-11-05 WO PCT/US2021/058162 patent/WO2022098936A1/en not_active Ceased
- 2021-11-05 CN CN202180086487.8A patent/CN116802738A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2019136762A (ru) | Идентификация, производство и применение неоантигенов | |
| JP2025143480A5 (https=) | ||
| JP2021514671A5 (https=) | ||
| JP2020532323A5 (https=) | ||
| Li et al. | The screening, identification, design and clinical application of tumor-specific neoantigens for TCR-T cells | |
| JP2025065197A5 (https=) | ||
| JP2020536553A5 (https=) | ||
| JPWO2020181240A5 (https=) | ||
| JP2021529750A5 (https=) | ||
| JP2025094018A5 (https=) | ||
| JP2025109722A (ja) | 癌の個別化ワクチン | |
| JP2023100828A5 (https=) | ||
| Komiyama et al. | Alu-derived cis-element regulates tumorigenesis-dependent gastric expression of GASDERMIN B (GSDMB) | |
| RU2018124997A (ru) | Идентификация, производство и применение неоантигенов | |
| CN113424264B (zh) | 用于生成个性化癌症疫苗的癌症突变选择 | |
| US20260057964A1 (en) | Method and system of targeting epitopes for neoantigen-based immunotherapy | |
| JPWO2022098936A5 (https=) | ||
| JP2025502689A (ja) | タンパク質発現のためのｍＲＮＡ及びそのための鋳型 | |
| EP4054726A1 (en) | Systems and methods for deconvoluting tumor ecosystems for personalized cancer therapy | |
| JP2023509540A (ja) | 新生抗原をスクリーニングする方法、システム及びその用途 | |
| Zhang et al. | Neoantigen DNA vaccines are safe, feasible, and capable of inducing neoantigen-specific immune responses in patients with triple negative breast cancer | |
| JPWO2020097393A5 (https=) | ||
| Tarek et al. | Computational prediction of vaccine potential epitopes and 3-dimensional structure of XAGE-1b for non-small cell lung cancer immunotherapy | |
| JP2004512021A5 (https=) | ||
| CN114164269A (zh) | 一种与肾透明细胞癌预后显著相关的潜在抗原、免疫分型及其构建方法和应用 |